There is evidence that different types of ferritic cancer cells can release HMGB1, a damage-related molecule, in a ferroptosis-dependent manner, and can then obtain the characteristics of immune stimulation and act as an adjuvant (Yamazaki et al., 2014; Yu et al., 2015; Wen et al., 2019). This evidence concerns the gene HMGB1 and cancer.